Answers are grounded in this paper and cite their sources.
Aysha Mendes explores the evidence behind teplizumab, reviews the wider immunotherapy landscape in T1D and considers the implications of this evolving field for prescribing practice
No takes yet. Share an insight, caveat, or question.
Aysha Mendes (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: